Prof Shaji K Kumar MD, Prof Simon J Harrison PhD, Prof Michele Cavo MD, Prof Javier de la Rubia MD, Rakesh Popat FRCPath, Prof Cristina Gasparetto MD, Prof Vania Hungria MD, Hans Salwender MD, Prof Kenshi Suzuki MD, Prof Inho Kim MD, Maika Onishi MD, Grace Ku MD, Rajvineeth Pothacamury MD, Muhammad Jalaluddin PhD, Jiewei Zeng PhD, Jeremy A Ross PhD, Edyta Dobkowska MD, Prof Philippe Moreau MD
{"title":"Venetoclax或安慰剂联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤（BELLINI）：一项随机3期研究的最终总生存期结果","authors":"Prof Shaji K Kumar MD, Prof Simon J Harrison PhD, Prof Michele Cavo MD, Prof Javier de la Rubia MD, Rakesh Popat FRCPath, Prof Cristina Gasparetto MD, Prof Vania Hungria MD, Hans Salwender MD, Prof Kenshi Suzuki MD, Prof Inho Kim MD, Maika Onishi MD, Grace Ku MD, Rajvineeth Pothacamury MD, Muhammad Jalaluddin PhD, Jiewei Zeng PhD, Jeremy A Ross PhD, Edyta Dobkowska MD, Prof Philippe Moreau MD","doi":"10.1016/s2352-3026(25)00139-5","DOIUrl":null,"url":null,"abstract":"The phase 3 BELLINI primary endpoint was met, showing superior progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma as assessed by an independent review committee. However, venetoclax showed increased early mortality. Here, we report the final overall survival analysis.","PeriodicalId":501011,"journal":{"name":"The Lancet Haematology","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study\",\"authors\":\"Prof Shaji K Kumar MD, Prof Simon J Harrison PhD, Prof Michele Cavo MD, Prof Javier de la Rubia MD, Rakesh Popat FRCPath, Prof Cristina Gasparetto MD, Prof Vania Hungria MD, Hans Salwender MD, Prof Kenshi Suzuki MD, Prof Inho Kim MD, Maika Onishi MD, Grace Ku MD, Rajvineeth Pothacamury MD, Muhammad Jalaluddin PhD, Jiewei Zeng PhD, Jeremy A Ross PhD, Edyta Dobkowska MD, Prof Philippe Moreau MD\",\"doi\":\"10.1016/s2352-3026(25)00139-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The phase 3 BELLINI primary endpoint was met, showing superior progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma as assessed by an independent review committee. However, venetoclax showed increased early mortality. Here, we report the final overall survival analysis.\",\"PeriodicalId\":501011,\"journal\":{\"name\":\"The Lancet Haematology\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Haematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s2352-3026(25)00139-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Haematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2352-3026(25)00139-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
The phase 3 BELLINI primary endpoint was met, showing superior progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma as assessed by an independent review committee. However, venetoclax showed increased early mortality. Here, we report the final overall survival analysis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
